AtriCure, Inc. (ATRC)

Market Cap	1.48B -0.9%
Revenue (ttm)	534.53M +14.9%
Net Income	-11.45M
EPS	-0.24
Shares Out	50.63M
PE Ratio	n/a
Forward PE	209.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	660,409
Open	28.00
Previous Close	28.21
Day's Range	27.68 - 29.32
52-Week Range	27.06 - 43.18
Beta	1.43
Analysts	Strong Buy
Price Target	51.17 (+74.76%)
Earnings Date	May 5, 2026

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 5, 2005
• Employees: 1,350
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRC
• Website: https://www.atricure.com

Financial Performance

In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price target is $51.17, which is an increase of 74.76% from the latest price.

Price Target

$51.17

(74.76% upside)

Analyst Consensus: Strong Buy